{"id":"https://openalex.org/W88308917","doi":null,"title":"Drug evaluation: Vilazodone--a combined SSRI and 5-HT1A partial agonist for the treatment of depression.","display_name":"Drug evaluation: Vilazodone--a combined SSRI and 5-HT1A partial agonist for the treatment of depression.","publication_year":2007,"publication_date":"2007-03-01","ids":{"openalex":"https://openalex.org/W88308917","mag":"88308917","pmid":"https://pubmed.ncbi.nlm.nih.gov/17351874"},"language":"en","primary_location":{"id":"pmid:17351874","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/17351874","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"IDrugs : the investigational drugs journal","raw_type":"Journal Article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5109307781","display_name":"Tomas de Paulis","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"Tomas de Paulis","raw_affiliation_strings":["Lntdp@earthlink.net"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lntdp@earthlink.net","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":["https://openalex.org/A5109307781"],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":2.1146,"has_fulltext":false,"cited_by_count":35,"citation_normalized_percentile":{"value":0.84632556,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":97},"biblio":{"volume":"10","issue":"3","first_page":"193","last_page":"201"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11071","display_name":"Treatment of Major Depression","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11071","display_name":"Treatment of Major Depression","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10056","display_name":"Neurotransmitter Receptor Influence on Behavior","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11337","display_name":"Tryptophan and brain disorders","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2803","display_name":"Biological Psychiatry"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/vilazodone","display_name":"vilazodone","score":1.0},{"id":"https://openalex.org/keywords/selective-serotonin-reuptake-inhibitors","display_name":"selective serotonin reuptake inhibitors","score":0.8370000123977661},{"id":"https://openalex.org/keywords/5-ht1a-receptor-partial-agonist","display_name":"5-HT1A receptor partial agonist","score":0.9559999704360962},{"id":"https://openalex.org/keywords/depression","display_name":"depression","score":0.6359999775886536},{"id":"https://openalex.org/keywords/antidepressant-efficacy","display_name":"antidepressant efficacy","score":0.9169999957084656},{"id":"https://openalex.org/keywords/forced-swim-test","display_name":"forced swim test","score":0.8510000109672546},{"id":"https://openalex.org/keywords/rem-sleep-deprivation","display_name":"REM sleep deprivation","score":0.6259999871253967},{"id":"https://openalex.org/keywords/ultrasonic-vocalizations","display_name":"ultrasonic vocalizations","score":0.8600000143051147},{"id":"https://openalex.org/keywords/anxiolytic-effects","display_name":"anxiolytic effects","score":0.9089999794960022},{"id":"https://openalex.org/keywords/paroxetine","display_name":"paroxetine","score":0.7139999866485596},{"id":"https://openalex.org/keywords/fluoxetine","display_name":"fluoxetine","score":1.0}],"concepts":[{"id":"https://openalex.org/C2779177272","wikidata":"https://www.wikidata.org/wiki/Q76560","display_name":"Antidepressant","level":3,"score":0.7645477056503296},{"id":"https://openalex.org/C58732023","wikidata":"https://www.wikidata.org/wiki/Q770260","display_name":"Partial agonist","level":4,"score":0.7593721151351929},{"id":"https://openalex.org/C2780092697","wikidata":"https://www.wikidata.org/wiki/Q7455053","display_name":"Serotonin reuptake inhibitor","level":4,"score":0.6593582630157471},{"id":"https://openalex.org/C2776134451","wikidata":"https://www.wikidata.org/wiki/Q422244","display_name":"Fluoxetine","level":4,"score":0.6428648233413696},{"id":"https://openalex.org/C2777828372","wikidata":"https://www.wikidata.org/wiki/Q408471","display_name":"Paroxetine","level":4,"score":0.6136716604232788},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5617393851280212},{"id":"https://openalex.org/C2778938600","wikidata":"https://www.wikidata.org/wiki/Q389934","display_name":"Agonist","level":3,"score":0.548848032951355},{"id":"https://openalex.org/C2777765862","wikidata":"https://www.wikidata.org/wiki/Q62903","display_name":"Anxiolytic","level":3,"score":0.504409909248352},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.46906256675720215},{"id":"https://openalex.org/C15744967","wikidata":"https://www.wikidata.org/wiki/Q9418","display_name":"Psychology","level":0,"score":0.4202689230442047},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.2997756004333496},{"id":"https://openalex.org/C2775864247","wikidata":"https://www.wikidata.org/wiki/Q167934","display_name":"Serotonin","level":3,"score":0.22436532378196716},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.16697880625724792},{"id":"https://openalex.org/C2781161787","wikidata":"https://www.wikidata.org/wiki/Q48360","display_name":"Hippocampus","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000069503","descriptor_name":"Vilazodone Hydrochloride","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001572","descriptor_name":"Benzofurans","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D001572","descriptor_name":"Benzofurans","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D001572","descriptor_name":"Benzofurans","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D002986","descriptor_name":"Clinical Trials as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D003863","descriptor_name":"Depression","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D004353","descriptor_name":"Drug Evaluation, Preclinical","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007211","descriptor_name":"Indoles","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D007211","descriptor_name":"Indoles","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D007211","descriptor_name":"Indoles","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D010330","descriptor_name":"Patents as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010879","descriptor_name":"Piperazines","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D010879","descriptor_name":"Piperazines","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D010879","descriptor_name":"Piperazines","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D015394","descriptor_name":"Molecular Structure","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017367","descriptor_name":"Selective Serotonin Reuptake Inhibitors","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D017367","descriptor_name":"Selective Serotonin Reuptake Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D017367","descriptor_name":"Selective Serotonin Reuptake Inhibitors","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D018687","descriptor_name":"Antidepressive Agents, Second-Generation","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D018687","descriptor_name":"Antidepressive Agents, Second-Generation","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D018687","descriptor_name":"Antidepressive Agents, Second-Generation","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D058825","descriptor_name":"Serotonin 5-HT1 Receptor Agonists","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true}],"locations_count":2,"locations":[{"id":"pmid:17351874","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/17351874","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"IDrugs : the investigational drugs journal","raw_type":"Journal Article"},{"id":"mag:88308917","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/17351874","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"PubMed","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.9907000064849854,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2079429358","https://openalex.org/W2114243524","https://openalex.org/W2024678540","https://openalex.org/W2331331536","https://openalex.org/W2322790968","https://openalex.org/W2074112764","https://openalex.org/W1994212562","https://openalex.org/W1990376788","https://openalex.org/W4210713619","https://openalex.org/W2404815024"],"abstract_inverted_index":{"Vilazodone":[0],"is":[1,16],"a":[2,10,131],"combined":[3],"selective":[4],"serotonin":[5],"reuptake":[6],"inhibitor":[7],"(SSRI)":[8],"and":[9,40,97],"5-HT(1A)":[11],"receptor":[12],"partial":[13],"agonist":[14],"that":[15,101,105,113],"being":[17],"developed":[18],"by":[19],"Clinical":[20],"Data":[21],"Inc":[22],"for":[23,94],"the":[24,49,62,114,127],"treatment":[25],"of":[26,57,67,106,116,145],"depression.":[27],"In":[28],"preclinical":[29],"studies,":[30],"vilazodone":[31,44,71,89,117],"compared":[32],"favorably":[33],"to":[34,104],"other":[35,137],"antidepressants":[36],"such":[37],"as":[38,118],"paroxetine":[39],"fluoxetine.":[41],"Orally":[42],"administered":[43,72],"inhibited":[45],"ultrasonic":[46],"vocalization":[47],"in":[48,61,69],"rat":[50],"after":[51],"electrical":[52],"foot":[53],"shock":[54],"(a":[55],"model":[56,66],"anxiolytic":[58],"activity).":[59],"Yet,":[60],"forced":[63],"swimming":[64],"test":[65],"depression":[68],"rats,":[70],"intraperitoneally":[73],"was":[74,102],"active":[75],"at":[76,81],"1":[77],"mg/kg":[78],"but":[79],"not":[80],"3":[82],"or":[83,140],"10":[84],"mg/kg.":[85],"During":[86],"clinical":[87,151],"trials,":[88],"completely":[90],"abolished":[91],"REM":[92],"sleep":[93],"8":[95],"h":[96],"demonstrated":[98],"antidepressant":[99,108,121,134],"efficacy":[100],"equal":[103],"current":[107],"therapeutics.":[109],"The":[110],"author":[111],"concludes":[112],"success":[115],"an":[119],"effective":[120],"agent":[122],"will":[123],"depend":[124],"on":[125],"whether":[126],"drug":[128],"can":[129,147],"produce":[130],"more":[132],"rapid":[133],"effect":[135],"than":[136],"SSRI":[138],"agents,":[139],"if":[141],"specific":[142],"genetic":[143],"markers":[144],"patients":[146],"be":[148],"associated":[149],"with":[150],"efficacy.":[152]},"counts_by_year":[{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":2},{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":2},{"year":2019,"cited_by_count":1},{"year":2018,"cited_by_count":1},{"year":2017,"cited_by_count":2},{"year":2016,"cited_by_count":3},{"year":2015,"cited_by_count":2},{"year":2014,"cited_by_count":1},{"year":2013,"cited_by_count":3},{"year":2012,"cited_by_count":2}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}